In addition to IL30 expression, treatment with Cas9hIL30-hPSCA NxPs effectively suppressed the expression of previously identified IL30-regulated oncogenes12, such as IGF1 (Fig. 6a, b; Supplementary Tables 7 and 8), which also functions as an angiogenic factor, and PTGS2 and NFKB1, which promote cancer cell survival and inflammation-associated cancer24. The gene discussed is PTGS2; the disease is cancer.